BR0009583A - Métodos para modular a resposta sexual em um ser humano, e para a manufatura de um medicamento para modular a resposta sexual em um ser humano - Google Patents

Métodos para modular a resposta sexual em um ser humano, e para a manufatura de um medicamento para modular a resposta sexual em um ser humano

Info

Publication number
BR0009583A
BR0009583A BR0009583-4A BR0009583A BR0009583A BR 0009583 A BR0009583 A BR 0009583A BR 0009583 A BR0009583 A BR 0009583A BR 0009583 A BR0009583 A BR 0009583A
Authority
BR
Brazil
Prior art keywords
human
modulate
sexual response
methods
drug
Prior art date
Application number
BR0009583-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Zorgniotti Andrian
Joseph S Podolski
Original Assignee
Zonagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zonagen Inc filed Critical Zonagen Inc
Publication of BR0009583A publication Critical patent/BR0009583A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
BR0009583-4A 1999-04-06 2000-04-06 Métodos para modular a resposta sexual em um ser humano, e para a manufatura de um medicamento para modular a resposta sexual em um ser humano BR0009583A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12791099P 1999-04-06 1999-04-06
PCT/US2000/009112 WO2000059491A2 (fr) 1999-04-06 2000-04-06 Methodes permettant de moduler la reponse sexuelle chez les humains

Publications (1)

Publication Number Publication Date
BR0009583A true BR0009583A (pt) 2002-06-11

Family

ID=22432589

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009583-4A BR0009583A (pt) 1999-04-06 2000-04-06 Métodos para modular a resposta sexual em um ser humano, e para a manufatura de um medicamento para modular a resposta sexual em um ser humano

Country Status (10)

Country Link
EP (1) EP1220666A2 (fr)
JP (1) JP2002541100A (fr)
KR (1) KR20020015310A (fr)
CN (1) CN1374861A (fr)
AU (1) AU4203600A (fr)
BR (1) BR0009583A (fr)
CA (1) CA2366903A1 (fr)
MX (1) MXPA01010021A (fr)
NO (1) NO20014827L (fr)
WO (1) WO2000059491A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130704D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd New use
US8939889B1 (en) 2013-08-22 2015-01-27 Coloplast A/S Pump bulb for an implantable penile prosthetic

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1221826B (it) * 1988-06-08 1990-07-12 Medico Harvey Srl Centro Preparato per uso topico per il trattamento terapeutico dell impotentia coeundi
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US5952006A (en) * 1995-09-29 1999-09-14 L.A.M. Pharmaceuticals, Llc Drug preparations for treating impotency
DK0996447T3 (da) * 1997-05-19 2006-11-13 Zonagen Inc Kombinationsbehandling til modulation af det humane seksuelle respons
AR017694A1 (es) * 1997-12-02 2001-09-12 West Christopher Una composicion para la administracion nasal de un farmaco para tratar la disfuncion erectil, el uso de dicha composicion en la fabricacion de unmedicamento, y un procedimiento para la preparacion de la composicion
US6011043A (en) * 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6486207B2 (en) * 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction

Also Published As

Publication number Publication date
WO2000059491A3 (fr) 2002-05-02
JP2002541100A (ja) 2002-12-03
KR20020015310A (ko) 2002-02-27
AU4203600A (en) 2000-10-23
CA2366903A1 (fr) 2000-10-12
CN1374861A (zh) 2002-10-16
WO2000059491A2 (fr) 2000-10-12
NO20014827D0 (no) 2001-10-04
NO20014827L (no) 2001-12-04
EP1220666A2 (fr) 2002-07-10
MXPA01010021A (es) 2002-07-30

Similar Documents

Publication Publication Date Title
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
CY1118849T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
CY1105834T1 (el) Χρηση παρασκευασματων για την εφαρμογη, στον κατω αναπνευστικο σωληνα αντισηπτικων παραγοντων και/ή παραγοντων που προαγουν την επουλωση των πληγων
DK0759757T3 (da) Orale, væskeformige alendronatformuleringer
TR200102067T2 (tr) Topikal formülasyonların mukoza boşluğuna verilmesi için aplikatör
ES2191329T3 (es) Utilizacion de xantofilos en medicamentos para la mejora de la duracion de la funcion muscular o el tratamiento de trastornos o enfermedades musculares.
BR9814378A (pt) Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase
CY1105707T1 (el) Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου
BR9809453A (pt) Composição de suprimento de medicamento para a liberação controlada de um ingrediente ativo dentro do meio-ambiente do estÈmago, uso da mesma, formulação farmacêutica, processo para obter gastrorretenção, para o tratamento ou profilaxia de uma doença, para melhorar a absorção gastrointestinal de medicamentos, e para a preparação de uma composição, e, estojo de partes para uso no tratamento de infecção por h. pylori.
PT777484E (pt) Formulacoes intravenosas de alendronato
CY1105849T1 (el) Χρηση αντισηπτικων στην εμπορικη κατασκευη φαρμακευτικου παρασκευασματος προς αποτροπη ή θepαπεια εναντι φλεγμονων εντος του ανθρωπινου σωματος
BR0115162A (pt) Tratamentos antitumorais eficazes
CY1114422T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει αρσενικωδες για τη θεραπευτικη αντιμετωπιση κακοηθειας
NO20004419D0 (no) Ny anvendelse
PT998287E (pt) Utilizacao de levobupivacaina
AR037524A1 (es) Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
BR0009583A (pt) Métodos para modular a resposta sexual em um ser humano, e para a manufatura de um medicamento para modular a resposta sexual em um ser humano
BR9909917A (pt) Novos usos e combinações de cabergoline e pramipexole
EE04330B1 (et) Levosimendani transmukoossed koostised ja nende kasutamine ravimi valmistamiseks
FI20011464A0 (fi) Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
DK1105141T3 (da) Phosphatidylcholin som et medikament med slimhindebeskyttende virkning
BR0004813A (pt) Constructos vesiculares marcados para citoproteção e tratamento de infecções por h. pylori
BR0112690A (pt) Medicamento contendo cilansetron para o tratamento de pacientes ibs masculinos não-obstipativos
BR0009327A (pt) Composição farmacêutica para a terapia de sintomas do trato urinário inferior
ES2175582T3 (es) Cromanos sustituidos con sulfonamida, procedimiento para su preparacion, su utilizacion como medicamento, asi como preparados farmaceuticos que los contienen.

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired